Proactive

Proactive genetic testing offers healthy adults without a strong personal or family history of disease an opportunity to learn about how their genes could potentially impact their health.

Invitae offers testing options that analyze genes that are well-established indicators of a significantly increased risk of developing hereditary cancers, cardiovascular conditions, and other medically important disorders. Learn more

Clinical Area: Proactive

147 genes

Invitae Genetic Health Screen

Learn More

Our most comprehensive proactive panel for healthy individuals analyzing over 145 genes related to inherited cancer and cardiovascular conditions, as well as several other medically actionable conditions.

61 genes

Invitae Cancer Screen

Learn More

Proactive panel for healthy individuals analyzing over 60 cancer-related genes.

77 genes

Invitae Cardio Screen

Learn More

Proactive panel for healthy individuals analyzing over 75 genes related to hereditary forms of cardiovascular disease.

11 genes

Invitae First Tier Population Screen

Learn More

Proactive panel for healthy individuals analyzing 11 genes related to inherited cancers and familial hypercholesterolemia.

59 genes

Invitae 59 Gene Actionable Disorders Panel

Learn More

A panel of 59 medically actionable genes prescribed by the American College of Medical Genetics and Genomics.

Clinical Area: Pharmacogenomics

25 genes

Invitae Pharmacogenomics Panel

Learn More

The Invitae Pharmacogenomics Panel analyzes a broad panel of genes that are known to impact drug metabolism and is intended to aid clinicians in selecting the most appropriate medications and dosages for their patients. Results should be used in combination with other clinical considerations and therapeutic drug monitoring to optimize treatment regimens and ensure safe medication use. Test results may also be used to help explain a patient’s medication history, including adverse drug events and treatment failures. All tests include a clinical decision support tool to help identify potential drug-drug and/or drug-gene interactions.